NCT02761187 is a clinical trial of No Intervention in Multiple Myeloma, sponsored by Takeda.

Who is sponsoring NCT02761187?

NCT02761187 is sponsored by Takeda.

What drugs are being tested in NCT02761187?

Interventions in NCT02761187: No Intervention.

What condition does NCT02761187 study?

NCT02761187 studies Multiple Myeloma.

Is NCT02761187 still recruiting?

NCT02761187 is currently terminated. Last updated 24 February 2025.

Are results published for NCT02761187?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-02-24 · How we verify

NCT02761187

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants

Terminated Results posted Last updated 24 February 2025

What this trial tests

trial testing No Intervention in Multiple Myeloma in 4,253 participants. Terminated before completion.

Timeline

1 July 2016

Primary endpoint
30 September 2021

30 September 2021

Quick facts

Lead sponsor	Takeda
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	4,253
Start date	1 July 2016
Primary completion	30 September 2021
Estimated completion	30 September 2021
Sites	137 locations across France, Colombia, Italy, Greece, Belgium, Taiwan, United Kingdom, Germany

Drugs / interventions tested

No Intervention

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Takeda — full company profile →

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Co-morbidities Primary · Baseline up to 5 years

Charlson Comorbidity Index (CCI) was used to represent number of participants with co-morbidities. CCI is a method of categorizing comorbidities of participants. Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and the sum of all the weights results in a single comorbidity score for a participant. A score of 0 = no comorbidities found, 1 = not ill, 2 = mildly ill, 3 = moderately ill, 4 = severely ill, and ≥5 = moribund. The higher the score, the more likely the predicted outcome resulted in mortality or higher resource u

0-1

Group	Value	95% CI
NDMM	1279
RRMM	1064

2-3

Group	Value	95% CI
NDMM	307
RRMM	247

4-5

Group	Value	95% CI
NDMM	66
RRMM	60

Group	Value	95% CI
NDMM	38
RRMM	19

Missing

Group	Value	95% CI
NDMM	71
RRMM	50

Number of Participants Diagnosed With Newly Diagnosed Multiple Myeloma (NDMM) and Relapsed/Refractory Multiple Myeloma (R/RMM) Primary · At Baseline

Participants diagnosed with NDMM and R/RMM were determined at the start of the study.

Group	Value	95% CI
NDMM	2338
RRMM	1915

Number of Participants With ECOG (Eastern Cooperative Oncology Group) Performance Status Primary · At Baseline

ECOG-PS measured on-therapy (time between first dose and last dose date with a 30-day lag) assessed participant's performance status on 6 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (\>50% of waking hours), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair \>50% of waking hours; 4=completely disabled, cannot carry on any self care, totally confined to bed/cha

Grade 0

Group	Value	95% CI
NDMM	714
RRMM	710

Grade 1

Group	Value	95% CI
NDMM	727
RRMM	559

Grade 2

Group	Value	95% CI
NDMM	171
RRMM	113

Grade 3

Group	Value	95% CI
NDMM	61
RRMM	22

Grade 4

Group	Value	95% CI
NDMM	13
RRMM	2

Missing

Group	Value	95% CI
NDMM	75
RRMM	34

Number of Participants With Myeloma Frailty Index Primary · At Baseline

Frailty is defined as the combination of unintentional weight loss, exhaustion, low physical activity, slow walking speed, and muscular weakness. The Myeloma Frailty Index is a composite index that was calculated using the points system, which produces a range of values from 0 to 5. Participants with score 0= fit, score 1= intermediate, and score ≥2= frail. Higher score indicates likeliness that the predicted outcome will result in frailty. The line of Therapy was determined at study entry.

0: Fit

Group	Value	95% CI
1st Line of Therapy	517
2nd Line of Therapy	428

1: Intermediate

Group	Value	95% CI
1st Line of Therapy	218
2nd Line of Therapy	202

≥2: Frail

Group	Value	95% CI
1st Line of Therapy	190
2nd Line of Therapy	130

Missing

Group	Value	95% CI
1st Line of Therapy	836
2nd Line of Therapy	680

Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) Primary · At Baseline

FISH methodology was reported with Yes/No results for the following tests: deletion (17p)/p53 \[Del(17p)/p53\], translocation (4,14) \[t(4,14)\], and translocation (14,16) \[t(14,16)\].

Del(17p)/p53

Group	Value	95% CI
1st Line of Therapy	208
2nd Line of Therapy	20
3rd Line of Therapy	7
4th Line of Therapy	4
>4th Line of Therapy	0
1st Line of Therapy	126
2nd Line of Therapy	23
3rd Line of Therapy	12
4th Line of Therapy	5
>4th Line of Therapy	0
1st Line of Therapy	950
2nd Line of Therapy	147
3rd Line of Therapy	55
4th Line of Therapy	24
>4th Line of Therapy	12
1st Line of Therapy	399
2nd Line of Therapy	17
3rd Line of Therapy	2
4th Line of Therapy	2
>4th Line of Therapy	0

t(4,14)

Group	Value	95% CI
1st Line of Therapy	208
2nd Line of Therapy	20
3rd Line of Therapy	7
4th Line of Therapy	4
>4th Line of Therapy	0
1st Line of Therapy	116
2nd Line of Therapy	24
3rd Line of Therapy	4
4th Line of Therapy	5
>4th Line of Therapy	3
1st Line of Therapy	957
2nd Line of Therapy	144
3rd Line of Therapy	63
4th Line of Therapy	25
>4th Line of Therapy	9
1st Line of Therapy	401
2nd Line of Therapy	18
3rd Line of Therapy	2
4th Line of Therapy	2
>4th Line of Therapy	0

t(14,16)

Group	Value	95% CI
1st Line of Therapy	208
2nd Line of Therapy	20
3rd Line of Therapy	7
4th Line of Therapy	4
>4th Line of Therapy	0
1st Line of Therapy	50
2nd Line of Therapy	7
3rd Line of Therapy	0
4th Line of Therapy	3
>4th Line of Therapy	0
1st Line of Therapy	1007
2nd Line of Therapy	157
3rd Line of Therapy	67
4th Line of Therapy	27
>4th Line of Therapy	12
1st Line of Therapy	416
2nd Line of Therapy	18
3rd Line of Therapy	2
4th Line of Therapy	2
>4th Line of Therapy	0

Number of Participants Evaluated for International Staging System (ISS)/ Revised (R)-ISS Stage Primary · At Baseline

ISS disease stages were defined as I:low risk, β2-Microglobulin\<3.5mg/L, albumin≥3.5g/dL, II:not stage I or III, III:high risk,β2-Microglobulin≥5.5mg/L). R-ISS is based on ISS, chromosomal abnormalities (CA), and lactate dehydrogenase (LDH). R-ISS disease stages were defined as I: ISS Stage I and standard risk CA by FISH and normal LDH (i.e. \<=300 U/L), II: Neither R-ISS Stage I nor Stage III, III: ISS Stage III and either high risk CA by FISH or high LDH (i.e. \>300 U/L).

ISS Stage I

Group	Value	95% CI
NDMM	395
RRMM	236

ISS Stage II

Group	Value	95% CI
NDMM	387
RRMM	267

ISS Stage III

Group	Value	95% CI
NDMM	520
RRMM	297

ISS Not Available

Group	Value	95% CI
NDMM	138
RRMM	376

ISS Missing

Group	Value	95% CI
NDMM	321
RRMM	264

R-ISS Stage I

Group	Value	95% CI
NDMM	127
RRMM	40

R-ISS Stage II

Group	Value	95% CI
NDMM	319
RRMM	145

R-ISS Stage III

Group	Value	95% CI
NDMM	76
RRMM	24

Duration of Treatment for Participants With and Without Stem Cell Transplant Primary · Baseline up to 5 years

Data was analyzed for participants with and without stem cell transplant for all enrolled population, included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data.

Group	Value	95% CI
1st Line of Therapy	4.5	0 – 45
2nd Line of Therapy	6.4	0 – 57
3rd Line of Therapy	9.2	0 – 80
4th Line of Therapy	11.5	0 – 68
>4th Line of Therapy	11.5	0 – 52

Overall Survival (OS) Primary · Baseline up to 5 years

Overall Survival was defined as the number of months from the index regimen start date within each line of therapy, starting with the line during study entry, until the date of death. The Kaplan Meier estimates was used for the analysis.

Group	Value	95% CI
1st Line of Therapy	NA	NA – NA
2nd Line of Therapy	47.67	45.34 – NA
3rd Line of Therapy	32.07	26.84 – 39.56
4th Line of Therapy	20.60	17.51 – 23.36
>4th Line of Therapy	13.44	10.91 – 15.90

Time to Next Therapy Primary · Baseline up to 5 years

The line of Therapy was determined at study entry. The Kaplan Meier estimates was used for the analysis.

Group	Value	95% CI
1st Line of Therapy	30.39	26.87 – 33.74
2nd Line of Therapy	15.44	13.63 – 17.08
3rd Line of Therapy	9.46	8.34 – 10.81
4th Line of Therapy	6.90	6.11 – 7.82
>4th Line of Therapy	5.95	5.16 – 6.70

Number of Participants With Stem Cell Transplant Primary · Baseline up to 5 years

Group	Value	95% CI
1st Line of Therapy	1790
2nd Line of Therapy	686
3rd Line of Therapy	458
4th Line of Therapy	249
>4th Line of Therapy	80

Number of Participants Receiving Different Treatment Combinations Secondary · Baseline up to 5 years

Bortezomib and Lenalidomide (VR)

Group	Value	95% CI
1st Line of Therapy	560
2nd Line of Therapy	86
3rd Line of Therapy	19
4th Line of Therapy	10

Bortezomib and Cyclophosphamide (VC)

Group	Value	95% CI
1st Line of Therapy	497
2nd Line of Therapy	99
3rd Line of Therapy	43
4th Line of Therapy	18

Bortezomib and Thalidomide (VT)

Group	Value	95% CI
1st Line of Therapy	272
2nd Line of Therapy	60
3rd Line of Therapy	10
4th Line of Therapy	11

Bortezomib and Melphalan (VM)

Group	Value	95% CI
1st Line of Therapy	75
2nd Line of Therapy	16
3rd Line of Therapy	8
4th Line of Therapy	3

Lenalidomide (R)

Group	Value	95% CI
1st Line of Therapy	21
2nd Line of Therapy	39
3rd Line of Therapy	22
4th Line of Therapy	5

Lenalidomide and Dexamethasone (RD)

Group	Value	95% CI
1st Line of Therapy	86
2nd Line of Therapy	218
3rd Line of Therapy	126
4th Line of Therapy	30

Cyclophosphamide and Thalidomide (CT)

Group	Value	95% CI
1st Line of Therapy	60
2nd Line of Therapy	37
3rd Line of Therapy	11
4th Line of Therapy	5

Melphalan and Thalidomide (MT)

Group	Value	95% CI
1st Line of Therapy	10
2nd Line of Therapy	3
3rd Line of Therapy	4
4th Line of Therapy	3

Number of Treatment Sequencing Secondary · Baseline up to 5 years

Drug classes were based on the earliest regimen in each corresponding Line of Therapy. The data for this outcome measure was analyzed as per line of therapy.

mAB based

Group	Value	95% CI
1st Line of Therapy	41
2nd Line of Therapy	77
3rd Line of Therapy	129

mAB/IMID based

Group	Value	95% CI
1st Line of Therapy	290
2nd Line of Therapy	213
3rd Line of Therapy	128

mAB/PI based

Group	Value	95% CI
1st Line of Therapy	156
2nd Line of Therapy	119
3rd Line of Therapy	69

mAB/alkalytor based

Group	Value	95% CI
1st Line of Therapy	2
2nd Line of Therapy	7
3rd Line of Therapy	6

mAB/IMID/PI based

Group	Value	95% CI
1st Line of Therapy	36
2nd Line of Therapy	14
3rd Line of Therapy	12

Cytotoxic

Group	Value	95% CI
1st Line of Therapy	74
2nd Line of Therapy	59
3rd Line of Therapy	49

IMID based

Group	Value	95% CI
1st Line of Therapy	515
2nd Line of Therapy	361
3rd Line of Therapy	118

PI based

Group	Value	95% CI
1st Line of Therapy	366
2nd Line of Therapy	204
3rd Line of Therapy	101

Adverse events — posted to ClinicalTrials.gov

Time frame: From start of study, until death, or the end of the study, whichever comes first (up to 5 years). Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

1st Line of Therapy

Serious: 269/1849 (15%)

Deaths: 351/1790

2nd Line of Therapy

Serious: 101/773 (13%)

Deaths: 418/1331

3rd Line of Therapy

Serious: 82/455 (18%)

Deaths: 420/1050

4th Line of Therapy

Serious: 43/239 (18%)

Deaths: 348/739

>4th Line of Therapy

Serious: 38/181 (21%)

Deaths: 234/453

Robustness Concerns: 1st Line of Therapy

Serious: 0

Deaths: 58/340

Robustness Concerns: 2nd Line of Therapy

Serious: 0

Deaths: 72/303

Robustness Concerns: 3rd Line of Therapy

Serious: 0

Deaths: 65/222

Robustness Concerns: 4th Line of Therapy

Serious: 0

Deaths: 32/86

Robustness Concerns: >4th Line of Therapy

Serious: 0

Deaths: 6/24

Robustness Concerns: Unknown Line of Therapy

Serious: 0

Deaths: 28/147

Serious adverse events (295 terms)

Reaction	System	1st Line of Therapy	2nd Line of Therapy	3rd Line of Therapy	4th Line of Therapy	>4th Line of Therapy	Robustness Concerns: 1st L…	Robustness Concerns: 2nd L…	Robustness Concerns: 3rd L…	Robustness Concerns: 4th L…	Robustness Concerns: >4th …	Robustness Concerns: Unkno…
Pneumonia	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—
Acute kidney injury	Renal and urinary disorders	—	—	—	—	—	—	—	—	—	—	—
Cardiac failure congestive	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Lower respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Sepsis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Septic shock	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—
Respiratory failure	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—
Febrile neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—
Pancytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—
Respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Plasma cell myeloma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—	—	—	—
Syncope	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—
Deep vein thrombosis	Vascular disorders	—	—	—	—	—	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—
Cellulitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Gastroenteritis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—

Other adverse events (250 terms — click to expand)

Reaction	System	1st Line of Therapy	2nd Line of Therapy	3rd Line of Therapy	4th Line of Therapy	>4th Line of Therapy	Robustness Concerns: 1st L…	Robustness Concerns: 2nd L…	Robustness Concerns: 3rd L…	Robustness Concerns: 4th L…	Robustness Concerns: >4th …	Robustness Concerns: Unkno…
Neuropathy peripheral	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Peripheral sensory neuropathy	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Rash maculo-papular	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Bone pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Polyneuropathy	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Influenza	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Neutrophil count decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Malaise	General disorders	—	—	—	—	—	—	—	—	—	—	—
Platelet count decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Hypoaesthesia	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—	—	—	—	—	—
Rash pruritic	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Bradycardia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—
Haematochezia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Fall	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—	—	—
White blood cell count decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Pneumonia, Pyrexia, Acute kidney injury, Cardiac failure congestive, Diarrhoea, Lower respiratory tract infection, Sepsis, Atrial fibrillation.

Data from ClinicalTrials.gov NCT02761187 adverse events section.

Sponsor's own description

The purpose of this study is to describe contemporary, real-world patterns of participant characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in participants with newly diagnosed \[ND\] multiple myeloma (MM) and participants with relapsed/refractory \[R/R\] MM.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.
Costello C, Davies FE, Cook G, Vela-Ojeda J, et al · · 2019 · cited 24× · PMID 30816809 · DOI 10.2217/fon-2019-0013
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Hájek R, Minařík J, Straub J, Pour L, et al · · 2021 · cited 21× · PMID 33769076 · DOI 10.2217/fon-2020-1225
New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.
Richardson PG, Kumar S, Laubach JP, Paba-Prada C, et al · · 2017 · cited 15× · PMID 28860887 · DOI 10.2147/jbm.s102328
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients.
Thompson MA, Boccadoro M, Leleu X, Vela-Ojeda J, et al · · 2023 · cited 8× · PMID 36641358 · DOI 10.1016/j.clml.2022.12.003
The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge.
Decaux O, Garlantézec R, Belhadj-Merzoug K, Macro M, et al · · 2024 · cited 7× · PMID 39050939 · DOI 10.46989/001c.121371
<i>In</i>-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Rifkin RM, Costello CL, Birhiray RE, Kambhampati S, et al · · 2024 · cited 3× · PMID 37807952 · DOI 10.2217/fon-2023-0272
Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis.
Puig N, Leleu X, Lee HC, Davies FE, et al · · 2026 · PMID 41528195 · DOI 10.1111/ejh.70079
Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 2020
· 2020

Verify or expand the search:

Other trials of No Intervention

Trials testing the same drug.

NCT07353099 — A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma · not yet recruiting
NCT07429942 — A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Recei · not yet recruiting
NCT07521917 — Child Abuse and Neglect Awareness Training in Nursing Students · NA · not yet recruiting
NCT07319832 — A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome · recruiting
NCT07425574 — A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults · recruiting

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Takeda trials

Trials by the same sponsor.

NCT05669729 — A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velagluceras · not yet recruiting
NCT07403968 — A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease · Phase 2 · not yet recruiting
NCT07293364 — A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema · NA · not yet recruiting
NCT07218393 — A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt · not yet recruiting
NCT07445087 — A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02761187 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Takeda
Last refreshed: 24 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02761187.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02761187

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (295 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of No Intervention

Other recruiting trials for Multiple Myeloma

Other Takeda trials

Verify against primary sources